Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 19 of 19 publications.

Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Mar;21(7):833-42. doi: 10.1080/14796694.2025.2464485

Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Mar;21(7):843-51. doi: 10.1080/14796694.2025.2463276

Ailawadhi S, Inocencio TJ, Mansfield C, Chintakayala P, Bussberg C, Chi L, Harnett J, Kroog GS, Rodriguez-Lorenc K, Ma Q. Patient preferences for triple-class–exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study. Future Oncol. 2025 Mar;21(7):853-65. doi: 10.1080/14796694.2025.2461430

Passamonti F, Korgaonkar S, Parikh RC, Chevli M, Yucel A, Rombi J, Jones S, Zissler D, Davis KL, Slaff S. Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib. Future Oncol. 2025 Feb;21(5):579-91. doi: 10.1080/14796694.2025.2454895

Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo JML, Mansfield C. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment. Future Oncol. 2024;20(28):2059-70. doi: 10.1080/14796694.2024.2348440

Diez-Campelo M, Yucel A, Goyal RK, Parikh RC, Esterberg E, Jimenez M, Sluga-O'Callaghan M, Miteva D, Xiao H, Germing U. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe. Future Oncol. 2024;20(27):1993-2004. doi: 10.1080/14796694.2024.2379228

Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, Caro N, Saliba T. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. 2024;20(22):1553-63. doi: 10.2217/fon-2023-1064

Paik PK, Goyal RK, Cai B, Price MA, Davis KL, Derrien Ansquer V, Caro N, Saliba TR. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023 Jan;19(3):217-28. doi: 10.2217/fon-2022-1133

Huisman MV, Teutsch C, Lu S, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Lohmann R, Gurusamy VK, Bartels DB, Lip GYH, GLORIA-AF Investigators. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. Clin Res Cardiol. 2022 May;111(5):548-59. doi: 10.1007/s00392-021-01957-1

Lip GYH, Kotalczyk A, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Marler S, Gurusamy VK, Huisman MV, GLORIA-AF Investigators. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. Clin Res Cardiol. 2022 May;111(5):560-73. doi: 10.1007/s00392-022-01996-2

DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Nov;17(33):4635-47. doi: 10.2217/fon-2021-0742

Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol. 2021 Jul;17(21):2759-68.

Mansfield C, Myers K, Klein K, Patel J, Nakasato A, Ling YL, Tarhini AA. Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncol. 2021 Jun;17(17):2151-67. doi: 10.2217/fon-2020-1193

Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol. 2020 Nov;16(31):2475-85. doi: 10.2217/fon-2020-0573

Vassilev ZP, Soriano Gabarro M, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtala J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. Future Oncol. 2020 Sep;16(25):1889-901. doi: 10.2217/fon-2020-0315

Darden C, Mitra D, McSorley D, Davis K, Band J, Iyer S. Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. Future Oncol. 2019 Jan;15(2):141-50. doi: 10.2217/fon-2018-0531

Abdul-Jawad Altisent O, Ferreira-Gonzalez I, Marsal JR, Ribera A, Auger C, Ortega G, Cascant P, Urena M, Del Blanco BG, Serra V, Sureda C, Igual A, Rovira A, González-Alujas MT, Gonzalez A, Puri R, Cuellar H, Tornos P, Rodes-Cabau J, Garcia-Dorado D. Neurological damage after transcatheter aortic valve implantation compared with surgical aortic valve replacement in intermediate risk patients. Clin Res Cardiol. 2016 Jun;105(6):508-17. doi: 10.1007/s00392-015-0946-9

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Cefalu WT, Wagner JD, Anthony MS. Hyperinsulinemia and central obesity in a non-human primate (macaca fascicularis) model for cardiovascular risk factors. Clin Res Cardiol. 1992;40:230A.